Developer docs
API playgroundTry for free, no card

Search company profiles

Resilia Pharmaceuticals

Full company profile

uuid003fiag

Namestring
Resilia Pharmaceuticals
Legal namestring
Resilia Pharmaceuticals, Inc.
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Resilia Pharmaceuticals is a privately held specialty pharmaceuticals company founded in 2020 and headquartered in Atlanta (Sandy Springs), Georgia. It operates as a dermatology-focused subsidiary of Peak Pharma Commercial Partners, applying a roll-up model in which it acquires or licenses FDA-approved therapeutics — primarily those that are clinically validated but commercially underpromoted — rather than developing novel molecules. Its marketed portfolio comprises five topical brands across dermatology and wound care: ECOZA® (econazole nitrate topical foam, 1%, antifungal), RECEDO® topical gel (scar treatment, recognized by the National Academy of Dermatology Nurse Practitioners as the #1 most prescribed scar treatment over the prior five years), NEOCERA® advanced cream, NEOSALUS® advanced cream/foam/lotion (wound and skin barrier care), and Solace® Eczema Cream (acquired via license in October 2021). The company does not disclose a proprietary technology platform; product assets and regulatory approvals are the core of its value.

Resilia monetizes these products through prescription pharmaceutical sales distributed across multiple channels: retail pharmacy wholesalers (with stated 2-day order fulfillment), the GoodRx pricing platform, Amazon Marketplace (for Solace), and — most strategically — an exclusive US distribution partnership with Mayne Pharma's DistributerRx subsidiary covering RECEDO and targeting specialist prescribers in plastic surgery and OB/GYN. Its go-to-market motion combines enterprise field sales executed through commercial partner ImpactBio, agency-of-record marketing via Excitant Healthcare Advertising, conference presence at NADNP and similar meetings, and patient-facing affordability programs (Resilia Savings Card and a Responsible Pricing Program). Customer segments are specialist healthcare prescribers (plastic surgery, OB/GYN, dermatology) and end patients, with revenue split between direct pharmaceutical product sales and structured per-prescription transaction fees from the DistributerRx partnership. Management is led by Executive Chairman Harsha Murthy (former King Pharmaceuticals, Eyetech, Konanda) and President/COO Mike Leone (former Bristol-Myers Squibb, Eyetech, Takeda).

Short descriptiontext

Resilia Pharmaceuticals is a privately held specialty pharma company that acquires and commercializes FDA-approved dermatology products. Founded in 2020 in Atlanta, it markets ECOZA, RECEDO, NEOSALUS, NEOCERA, and Solace to specialist prescribers and patients across the United States.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSandy Springs, United States
HQ citystring
Sandy Springs
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, dermatology therapeutics, topical medications, prescription skincare, wound care products
Industry2 codes
PRIMARYHLAIACAL
Dermatology Specialty Pharmaceuticals
SECONDARYHLAIAAAK
Dermatology & Aesthetics Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Dermatology Pharmaceuticals
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Resilia generates revenue from the sale of FDA-approved pharmaceutical products across dermatology and specialty therapeutic areas. Products include ECOZA (econazole nitrate topical foam for fungal infections), RECEDO (topical gel for scar treatment), NEOCERA (advanced cream), and NEOSALUS (advanced cream, foam, or lotion for wound care). Revenue is derived from prescription volumes filled through retail pharmacies and specialty distributors.

resiliapharma.com
2Distribution Partnership Revenue
TypeTransaction Fee
Description

Under the exclusive US distribution partnership with Mayne Pharma/DistributerRx for RECEDO topical gel, Resilia receives structured fixed fees per prescription filled. This represents a recurring transaction-based revenue stream tied to prescription volume through a digital prescription distribution platform.

grafa.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Marketing or Sales, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1ECOZA
Description

ECOZA® (econazole nitrate) Topical Foam, 1% - antifungal treatment product

resiliapharma.com
+4 more records
Core offering1 text field

Resilia Pharmaceuticals acquires, licenses, and commercializes FDA-approved specialty dermatology therapeutics. Its portfolio includes prescription topical products for fungal infections (ECOZA), scar treatment (RECEDO), advanced wound care (NEOCERA, NEOSALUS), and eczema (Solace). Products are distributed through retail pharmacies, specialty wholesalers, and an exclusive US digital prescription distribution partnership with Mayne Pharma/DistributerRx.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • RECEDO is the #1 most prescribed scar treatment over the past 5 years (National Academy of Dermatology Nurse Practitioners, November 2021)
Product overview1 text field

Resilia Pharmaceuticals is a privately held specialty pharmaceuticals company focused on acquiring high-value but underpromoted therapeutics as well as high-value therapeutics in late-stage development. The company's product portfolio consists of FDA-approved topical pharmaceutical products: ECOZA (econazole nitrate) Topical Foam 1% for antifungal treatment; RECEDO Topical Gel for scar treatment (the #1 most prescribed scar treatment over the past 5 years per NADNP); NEOCERA Advanced Cream; and NEOSALUS Advanced Cream, Foam, and Lotion. The company also acquired rights to commercialize Solace Eczema Cream. Resilia operates as a Peak Pharma Commercial Partners company, with products available through retail pharmacies and GoodRx.

Product and service5 records
1ECOZA (econazole nitrate) Topical Foam, 1%
CategoryPrescription Dermatology - Antifungal
Description

FDA-approved antifungal topical foam containing 1% econazole nitrate, used for the topical treatment of fungal skin infections. Prescribed by dermatology and primary care providers and dispensed through retail pharmacies.

2RECEDO Topical Gel
CategoryPrescription Dermatology - Scar Treatment
Description

FDA-approved prescription topical gel for scar treatment. Recognized by the National Academy of Dermatology Nurse Practitioners (NADNP) as the #1 most prescribed scar treatment over the past 5 years. Targeted to specialist healthcare prescribers in plastic surgery and OB/GYN practices for advanced scar care.

3NEOCERA Advanced Cream
CategoryPrescription Dermatology - Advanced Skincare
Description

NEOCERA is an FDA-approved advanced cream dermatology/skincare product within Resilia's portfolio, intended for prescription dermatological use.

4NEOSALUS Advanced Cream, Foam, or Lotion
CategoryPrescription Dermatology - Wound Care
Description

NEOSALUS is an FDA-approved advanced cream, foam, or lotion formulation for prescription dermatological and wound care use. The cream and lotion forms were relaunched in May 2023.

5Solace Eczema Cream
CategoryConsumer Dermatology - Eczema Treatment
Description

Solace Eczema Cream is an eczema treatment product licensed for commercialization by Resilia Pharmaceuticals. Distributed via Amazon Marketplace to expand direct-to-consumer access to the dermatology portfolio.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-06-01
Description

Mayne Pharma Group's wholly-owned subsidiary DistributerRx secured an exclusive distribution partnership with Resilia Pharmaceuticals to distribute RECEDO topical gel across the United States. DistributerRx leverages its digital prescription distribution platform and receives structured fixed fees per prescription filled. The partnership targets expansion of RECEDO's adoption among specialist healthcare prescribers in plastic surgery and OB/GYN practices for advanced scar care.

2Peak Pharma Commercial Partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Resilia is a Peak Pharma Commercial Partners company. Peak Pharma provides the commercial infrastructure, capital backing, and operational framework for Resilia's pharmaceutical business. Resilia operates as the dermatology-focused subsidiary under the Peak Pharma umbrella.

resiliapharma.com
Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

ImpactBio was appointed as commercial partner for Resilia's dermatology product line in February 2021, supporting market access, prescriber engagement, and commercial execution for products including ECOZA, RECEDO, NEOCERA, and NEOSALUS.

Strategic tierMajorTypeGTM or Marketing Partner
Description

Excitant Healthcare Advertising was appointed as agency of record for Resilia's dermatology product line in February 2021, providing multi-channel marketing, advertising, and promotional execution support across the portfolio.

Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global medical products company with a dedicated Advanced Wound Care franchise. Comparable to Resilia across advanced skin and wound care therapeutics, with a far larger commercial footprint and proprietary pipeline.

TypeDirect peer
Description

Israel/US dermatology specialty pharma developing and commercializing topical branded dermatology products. Comparable in therapeutic focus and product development approach to Resilia's branded dermatology portfolio.

TypeBroad incumbent
Description

Global dermatology specialty pharma leader with a broad prescription and aesthetic dermatology portfolio. Overlaps directly with Resilia across dermatology therapeutics and wound care, but at much larger scale and with proprietary R&D.

TypeBroad incumbent
Description

Large diversified pharma whose Ortho Dermatologics division is a major US prescription dermatology franchise including topical steroids, antifungals, and acne/eczema products. Competes head-on with Resilia's branded dermatology portfolio.

TypeBroad incumbent
Description

Australian specialty pharma with US operations across dermatology, women's health, and generics. Direct strategic partner to Resilia via DistributerRx and a broad incumbent in the same dermatology/endocrinology channels.

TypeDirect peer
Description

Commercial-stage dermatology company that acquires and markets branded dermatology products. Runs a similar 'acquire and commercialize derisked assets' model to Resilia, with overlapping prescriber channels.

TypeDirect peer
Description

Small US dermatology specialty pharma commercializing branded topical therapeutics. Similar profile to Resilia: focused dermatology portfolio, lean team, and reliance on prescriber channels for adoption.

TypeBroad incumbent
Description

Global medical device and wound care company. Competes with Resilia's NEOCERA and NEOSALUS wound care/advanced skin products from a much larger, diversified advanced wound care platform.

TypeDirect peer
Description

US clinical-stage and commercial specialty pharma focused on dermatology and immunology. Closely comparable in size, therapeutic focus, and product-acquisition model to Resilia, with branded dermatology assets in similar indications.

TypeDirect peer
Description

US specialty pharma focused on acquiring and commercializing branded ophthalmic and dermatology products. Closely mirrors Resilia's acquire-and-commercialize strategy with a similarly lean operating model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Resilia Pharmaceuticals

Specialty Dermatology Pharmaceuticalsresiliapharma.com

Resilia Pharmaceuticals is a privately held specialty pharma company that acquires and commercializes FDA-approved dermatology products. Founded in 2020 in Atlanta, it markets ECOZA, RECEDO, NEOSALUS, NEOCERA, and Solace to specialist prescribers and patients across the United States.

What Resilia Pharmaceuticals does

Resilia Pharmaceuticals is a privately held specialty pharmaceuticals company founded in 2020 and headquartered in Atlanta (Sandy Springs), Georgia. It operates as a dermatology-focused subsidiary of Peak Pharma Commercial Partners, applying a roll-up model in which it acquires or licenses FDA-approved therapeutics — primarily those that are clinically validated but commercially underpromoted — rather than developing novel molecules. Its marketed portfolio comprises five topical brands across dermatology and wound care: ECOZA® (econazole nitrate topical foam, 1%, antifungal), RECEDO® topical gel (scar treatment, recognized by the National Academy of Dermatology Nurse Practitioners as the #1 most prescribed scar treatment over the prior five years), NEOCERA® advanced cream, NEOSALUS® advanced cream/foam/lotion (wound and skin barrier care), and Solace® Eczema Cream (acquired via license in October 2021). The company does not disclose a proprietary technology platform; product assets and regulatory approvals are the core of its value.

Resilia monetizes these products through prescription pharmaceutical sales distributed across multiple channels: retail pharmacy wholesalers (with stated 2-day order fulfillment), the GoodRx pricing platform, Amazon Marketplace (for Solace), and — most strategically — an exclusive US distribution partnership with Mayne Pharma's DistributerRx subsidiary covering RECEDO and targeting specialist prescribers in plastic surgery and OB/GYN. Its go-to-market motion combines enterprise field sales executed through commercial partner ImpactBio, agency-of-record marketing via Excitant Healthcare Advertising, conference presence at NADNP and similar meetings, and patient-facing affordability programs (Resilia Savings Card and a Responsible Pricing Program). Customer segments are specialist healthcare prescribers (plastic surgery, OB/GYN, dermatology) and end patients, with revenue split between direct pharmaceutical product sales and structured per-prescription transaction fees from the DistributerRx partnership. Management is led by Executive Chairman Harsha Murthy (former King Pharmaceuticals, Eyetech, Konanda) and President/COO Mike Leone (former Bristol-Myers Squibb, Eyetech, Takeda).

Resilia Pharmaceuticals firmographics

Firmographics
Name
Resilia Pharmaceuticals
Legal name
Resilia Pharmaceuticals, Inc.
Website
https://resiliapharma.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Resilia Pharmaceuticals is a privately held specialty pharma company that acquires and commercializes FDA-approved dermatology products. Founded in 2020 in Atlanta, it markets ECOZA, RECEDO, NEOSALUS, NEOCERA, and Solace to specialist prescribers and patients across the United States.
Ownership category
akta.pro rank

Resilia Pharmaceuticals industry classification

Industry
Product category
Specialty Dermatology Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAL
Dermatology Specialty Pharmaceuticals
SECONDARYHLAIAAAK
Dermatology & Aesthetics Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Specialty pharmaceuticals
  • Dermatology therapeutics
  • Topical medications
  • Prescription skincare
  • Wound care products

Where Resilia Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Sandy Springs
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Resilia Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Marketing or Sales, Personnel, Operations, Others

Revenue model

  1. Pharmaceutical Product Sales: Resilia generates revenue from the sale of FDA-approved pharmaceutical products across dermatology and specialty therapeutic areas. Products include ECOZA (econazole nitrate topical foam for fungal infections), RECEDO (topical gel for scar treatment), NEOCERA (advanced cream), and NEOSALUS (advanced cream, foam, or lotion for wound care). Revenue is derived from prescription volumes filled through retail pharmacies and specialty distributors.
  2. Distribution Partnership Revenue: Under the exclusive US distribution partnership with Mayne Pharma/DistributerRx for RECEDO topical gel, Resilia receives structured fixed fees per prescription filled. This represents a recurring transaction-based revenue stream tied to prescription volume through a digital prescription distribution platform.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Resilia Pharmaceuticals product offering

Product offering

Core offering

Resilia Pharmaceuticals acquires, licenses, and commercializes FDA-approved specialty dermatology therapeutics. Its portfolio includes prescription topical products for fungal infections (ECOZA), scar treatment (RECEDO), advanced wound care (NEOCERA, NEOSALUS), and eczema (Solace). Products are distributed through retail pharmacies, specialty wholesalers, and an exclusive US digital prescription distribution partnership with Mayne Pharma/DistributerRx.

Product overview

Resilia Pharmaceuticals is a privately held specialty pharmaceuticals company focused on acquiring high-value but underpromoted therapeutics as well as high-value therapeutics in late-stage development. The company's product portfolio consists of FDA-approved topical pharmaceutical products: ECOZA (econazole nitrate) Topical Foam 1% for antifungal treatment; RECEDO Topical Gel for scar treatment (the #1 most prescribed scar treatment over the past 5 years per NADNP); NEOCERA Advanced Cream; and NEOSALUS Advanced Cream, Foam, and Lotion. The company also acquired rights to commercialize Solace Eczema Cream. Resilia operates as a Peak Pharma Commercial Partners company, with products available through retail pharmacies and GoodRx.

Differentiator

Problem solved

Functional benefit

Brands

  • ECOZA: ECOZA® (econazole nitrate) Topical Foam, 1% - antifungal treatment product
  • RECEDO
  • NEOCERA
  • NEOSALUS
  • Solace

Products and services

  • ECOZA (econazole nitrate) Topical Foam, 1% FDA-approved antifungal topical foam containing 1% econazole nitrate, used for the topical treatment of fungal skin infections. Prescribed by dermatology and primary care providers and dispensed through retail pharmacies.
  • RECEDO Topical Gel FDA-approved prescription topical gel for scar treatment. Recognized by the National Academy of Dermatology Nurse Practitioners (NADNP) as the #1 most prescribed scar treatment over the past 5 years. Targeted to specialist healthcare prescribers in plastic surgery and OB/GYN practices for advanced scar care.
  • NEOCERA Advanced Cream NEOCERA is an FDA-approved advanced cream dermatology/skincare product within Resilia's portfolio, intended for prescription dermatological use.
  • NEOSALUS Advanced Cream, Foam, or Lotion NEOSALUS is an FDA-approved advanced cream, foam, or lotion formulation for prescription dermatological and wound care use. The cream and lotion forms were relaunched in May 2023.
  • Solace Eczema Cream Solace Eczema Cream is an eczema treatment product licensed for commercialization by Resilia Pharmaceuticals. Distributed via Amazon Marketplace to expand direct-to-consumer access to the dermatology portfolio.

Quantifiable outcome

  • RECEDO is the #1 most prescribed scar treatment over the past 5 years (National Academy of Dermatology Nurse Practitioners, November 2021)

Companies that use Resilia Pharmaceuticals

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Resilia Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Resilia Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and major.

  • Mayne Pharma Group / DistributerRxcoreChannel Partner/ Reseller/ Distributor · 1 June 2026Mayne Pharma Group's wholly-owned subsidiary DistributerRx secured an exclusive distribution partnership with Resilia Pharmaceuticals to distribute RECEDO topical gel across the United States. DistributerRx leverages its digital prescription distribution platform and receives structured fixed fees per prescription filled. The partnership targets expansion of RECEDO's adoption among specialist healthcare prescribers in plastic surgery and OB/GYN practices for advanced scar care.
  • Peak Pharma Commercial PartnerscoreStrategic or Co-development PartnerResilia is a Peak Pharma Commercial Partners company. Peak Pharma provides the commercial infrastructure, capital backing, and operational framework for Resilia's pharmaceutical business. Resilia operates as the dermatology-focused subsidiary under the Peak Pharma umbrella.
  • ImpactBiomajorChannel Partner/ Reseller/ DistributorImpactBio was appointed as commercial partner for Resilia's dermatology product line in February 2021, supporting market access, prescriber engagement, and commercial execution for products including ECOZA, RECEDO, NEOCERA, and NEOSALUS.
  • Excitant Healthcare AdvertisingmajorGTM or Marketing PartnerExcitant Healthcare Advertising was appointed as agency of record for Resilia's dermatology product line in February 2021, providing multi-channel marketing, advertising, and promotional execution support across the portfolio.

Scale indicators3 records

Recent moves2 records

Expansion highlights5 records

Resilia Pharmaceuticals competitors and assessment

Company assessment

Broad incumbents

  • ConvaTec: Global medical products company with a dedicated Advanced Wound Care franchise. Comparable to Resilia across advanced skin and wound care therapeutics, with a far larger commercial footprint and proprietary pipeline.
  • Galderma: Global dermatology specialty pharma leader with a broad prescription and aesthetic dermatology portfolio. Overlaps directly with Resilia across dermatology therapeutics and wound care, but at much larger scale and with proprietary R&D.
  • Bausch Health (Ortho Dermatologics): Large diversified pharma whose Ortho Dermatologics division is a major US prescription dermatology franchise including topical steroids, antifungals, and acne/eczema products. Competes head-on with Resilia's branded dermatology portfolio.
  • Mayne Pharma Group: Australian specialty pharma with US operations across dermatology, women's health, and generics. Direct strategic partner to Resilia via DistributerRx and a broad incumbent in the same dermatology/endocrinology channels.
  • Smith & Nephew (Advanced Wound Management): Global medical device and wound care company. Competes with Resilia's NEOCERA and NEOSALUS wound care/advanced skin products from a much larger, diversified advanced wound care platform.

Direct peers

  • Sol-Gel Technologies: Israel/US dermatology specialty pharma developing and commercializing topical branded dermatology products. Comparable in therapeutic focus and product development approach to Resilia's branded dermatology portfolio.
  • Journey Medical: Commercial-stage dermatology company that acquires and markets branded dermatology products. Runs a similar 'acquire and commercialize derisked assets' model to Resilia, with overlapping prescriber channels.
  • Verrica Pharmaceuticals: Small US dermatology specialty pharma commercializing branded topical therapeutics. Similar profile to Resilia: focused dermatology portfolio, lean team, and reliance on prescriber channels for adoption.
  • Aclaris Therapeutics: US clinical-stage and commercial specialty pharma focused on dermatology and immunology. Closely comparable in size, therapeutic focus, and product-acquisition model to Resilia, with branded dermatology assets in similar indications.
  • Harrow Health: US specialty pharma focused on acquiring and commercializing branded ophthalmic and dermatology products. Closely mirrors Resilia's acquire-and-commercialize strategy with a similarly lean operating model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Resilia Pharmaceuticals social profiles

Digital presence

Resilia Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Resilia Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles2 records

Resilia Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Resilia Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Resilia Pharmaceuticals

What does Resilia Pharmaceuticals do?

Resilia Pharmaceuticals acquires, licenses, and commercializes FDA-approved specialty dermatology therapeutics. Its portfolio includes prescription topical products for fungal infections (ECOZA), scar treatment (RECEDO), advanced wound care (NEOCERA, NEOSALUS), and eczema (Solace). Products are distributed through retail pharmacies, specialty wholesalers, and an exclusive US digital prescription distribution partnership with Mayne Pharma/DistributerRx.

Is Resilia Pharmaceuticals a public or private company?

Resilia Pharmaceuticals is a private company. It is classified as corporate owned and is currently operating.

When was Resilia Pharmaceuticals founded?

Resilia Pharmaceuticals was founded in 2020. It employs 11 to 50 people.

Where is Resilia Pharmaceuticals based?

Resilia Pharmaceuticals is headquartered in Sandy Springs, United States, in the North America region.

How does Resilia Pharmaceuticals make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are distribution Partnership Revenue.

Who are Resilia Pharmaceuticals's main competitors?

Broad incumbents on record are ConvaTec, Galderma, Bausch Health (Ortho Dermatologics), Mayne Pharma Group and Smith & Nephew (Advanced Wound Management). Direct peers are Sol-Gel Technologies, Journey Medical, Verrica Pharmaceuticals, Aclaris Therapeutics and Harrow Health.

Does Resilia Pharmaceuticals have an API?

No public API is recorded for Resilia Pharmaceuticals.

What industry is Resilia Pharmaceuticals in?

Resilia Pharmaceuticals's product category is Specialty Dermatology Pharmaceuticals. Its primary akta.pro industry code is HLAIACAL, Dermatology Specialty Pharmaceuticals, with a secondary code of HLAIAAAK, Dermatology & Aesthetics Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireResilia Pharmaceuticals Announces Return to Market of Neosalus® Cream and Neosalus® LotionResilia Pharmaceuticals has resumed the market availability of its Neosalus® Cream and Neosalus® Lotion, prescription products for skin disorders that were previously unavailable due to supply chain disruptions caused by the COVID-19 crisis. This relaunch follows another recent product return and aims to restore supply for patients and prescribers nationwide.PR NewswireResilia Pharmaceuticals Acquires License to Commercialize Solace™ Eczema Cream in the United StatesResilia Pharmaceuticals, Inc. announced the signing of a license agreement with Pelle Ventures, LLC to commercialize Solace™ Eczema Cream as an over-the-counter product in the United States. This agreement grants Resilia the rights to make, market, and sell the previously prescription-only medical device, which helps control eczema flares using skin-building blocks like ceramides and fatty acids. Financial terms of the transaction were not disclosed.American City Business JournalsResilia Pharmaceuticals, Inc. BizSpotlightResilia Pharmaceuticals, Inc., a new Atlanta-based dermatology company, has officially begun operations, focusing on a range of prescription products. Backed by Peak Pharma Commercial Partners, Resilia offers products that aim to improve patient outcomes in dermatology. The company's product line is already approved and marketed in the United States, targeting conditions like athlete's foot and various dermatoses.PR NewswireNew Dermatology Company Resilia Pharmaceuticals Begins OperationsPeak Pharma Commercial Partners announced the creation and start of operations of Resilia Pharmaceuticals, a new dermatology-focused portfolio company based in Atlanta, Georgia. The new company launched with four branded prescription dermatology products—Ecoza, Recedo, Neosalus, and Neocera—all currently approved and marketed in the US market. The senior leadership team includes Executive Chairman Harsha Murthy, President & CEO Andrew Shales, and COO Mike Leone.